Development and Validation of a Novel Leishmania donovani Screening Cascade for High-Throughput Screening Using a Novel Axenic Assay with High Predictivity of Leishmanicidal Intracellular Activity

PLoS Neglected Tropical Diseases

Volumn 9, Issue 9, 2015, Pages

  Nühs, Andrea ^a   De Rycker, Manu ^a   Manthri, Sujatha ^a   Comer, Eamon ^b   Scherer, Christina A ^b   Schreiber, Stuart L ^b   Ioset, Jean Robert ^c   Gray, David W ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c Drugs for Neglected Diseases Initiative   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTILEISHMANIAL AGENT; MILTEFOSINE; RESAZURIN; ANTIPROTOZOAL AGENT;

AMASTIGOTE; ARTICLE; AXENIC ASSAY; CELL ASSAY; CONTROLLED STUDY; HIGH THROUGHPUT SCREENING; HISTORIC AXENIC ASSAY; HUMAN; HUMAN CELL; INTRAMACROPHAGE ASSAY; LEISHMANIA DONOVANI; LIMIT OF DETECTION; NONHUMAN; SCREENING TEST; STRUCTURE ACTIVITY RELATION; VISCERAL LEISHMANIASIS; AXENIC CULTURE; DRUG DEVELOPMENT; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; LEISHMANIASIS, VISCERAL; PARASITOLOGY; PREDICTIVE VALUE; PROCEDURES; VALIDATION STUDY;

ANTIPROTOZOAL AGENTS; AXENIC CULTURE; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; PREDICTIVE VALUE OF TESTS;

EID: 84943196022     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004094     Document Type: Article

References (45)

1. WHO. Sustaining the drive to overcome the global impact of neglected tropical diseases: second WHO report on neglected diseases. WHO Library Cataloguing-in-Publication Data. 2013.
2. Desjeux P, Leishmaniasis. Public health aspects and control. Clinics in dermatology. 1996;14(5):417–23. 8889319.
3. Desjeux P, Leishmaniasis: current situation and new perspectives. Comparative Immunology, Microbiology and Infectious Diseases. 2004;27(5):305–18. 15225981
4. Yanik M, Gurel MS, Simsek Z, Kati M, The psychological impact of cutaneous leishmaniasis. Clinical and experimental dermatology. 2004;29(5):464–7. 15347324
5. McGwire BS, Satoskar AR, Leishmaniasis: clinical syndromes and treatment. QJM: monthly journal of the Association of Physicians. 2014;107(1):7–14.
6. Monge-Maillo B, Lopez-Velez R, Therapeutic options for visceral leishmaniasis. Drugs. 2013;73(17):1863–88. doi: 10.1007/s40265-013-0133-0 24170666
7. Ready PD, Epidemiology of visceral leishmaniasis. Clinical epidemiology. 2014;6:147–54. doi: 10.2147/CLEP.S44267 24833919
8. De Corte BL, From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. Journal of medicinal chemistry. 2005;48(6):1689–96. 15771411
9. Keller TH, Shi PY, Wang QY, Anti-infectives: can cellular screening deliver? Current opinion in chemical biology. 2011;15(4):529–33. doi: 10.1016/j.cbpa.2011.06.007 21723774
10. Callahan HL, Portal AC, Devereaux R, Grogl M, An axenic amastigote system for drug screening. Antimicrob Agents Chemother. 1997;41(4):818–22. 9087496
11. Monte-Alegre A, Ouaissi A, Sereno D, Leishmania amastigotes as targets for drug screening. Kinetoplastid Biol Dis. 2006;5:6. 17059597
12. Shimony O, Jaffe CL, Rapid fluorescent assay for screening drugs on Leishmania amastigotes. J Microbiol Methods. 2008;75(2):196–200. doi: 10.1016/j.mimet.2008.05.026 18573286
13. Debrabant A, Joshi MB, Pimenta PFP, Dwyer DM, Generation of Leishmania donovani axenic amastigotes: their growth and biological characteristics. International Journal for Parasitology. 2004;34(2):205–17. 15037106
14. Holzer TR, McMaster WR, Forney JD, Expression profiling by whole-genome interspecies microarray hybridization reveals differential gene expression in procyclic promastigotes, lesion-derived amastigotes, and axenic amastigotes in Leishmania mexicana. Mol Biochem Parasitol. 2006;146(2):198–218. Epub 2006/01/25. doi: 10.1016/j.molbiopara.2005.12.009 16430978.
15. Li Q, Zhao Y, Ni B, Yao C, Zhou Y, Xu W, et al. Comparison of the expression profiles of promastigotes and axenic amastigotes in Leishmania donovani using serial analysis of gene expression. Parasitol Res. 2008;103(4):821–8. Epub 2008/06/24. doi: 10.1007/s00436-008-1048-7 18568446
16. Pescher P, Blisnick T, Bastin P, Spath GF, Quantitative proteome profiling informs on phenotypic traits that adapt Leishmania donovani for axenic and intracellular proliferation. Cell Microbiol. 2011. Epub 2011/04/20.
17. Vermeersch M, da Luz RI, Tote K, Timmermans JP, Cos P, Maes L, In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob Agents Chemother. 2009;53(9):3855–9. Epub 2009/06/24. doi: 10.1128/AAC.00548-09 19546361
18. De Rycker M, Hallyburton I, Thomas J, Campbell L, Wyllie S, Joshi D, et al. Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay. Antimicrobial agents and chemotherapy. 2013;57(7):2913–22. Epub 2013/04/11. doi: 10.1128/AAC.02398-12 23571538
19. Mikus J, Steverding D, A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue. Parasitology international. 2000;48(3):265–9. 11227767
20. Sereno D, Cordeiro da Silva A, Mathieu-Daude F, Ouaissi A, Advances and perspectives in Leishmania cell based drug-screening procedures. Parasitology international. 2007;56(1):3–7. 17079188
21. Siqueira-Neto JL, Song OR, Oh H, Sohn JH, Yang G, Nam J, et al. Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds. PLoS Negl Trop Dis. 2010;4(5):e675. Epub 2010/05/11. doi: 10.1371/journal.pntd.0000675 20454559
22. De Muylder G, Ang KK, Chen S, Arkin MR, Engel JC, McKerrow JH, A Screen against Leishmania Intracellular Amastigotes: Comparison to a Promastigote Screen and Identification of a Host Cell-Specific Hit. PLoS Negl Trop Dis. 2011;5(7):e1253. Epub 2011/08/04. doi: 10.1371/journal.pntd.0001253 21811648
23. Rosenzweig D, Smith D, Opperdoes F, Stern S, Olafson RW, Zilberstein D, Retooling Leishmania metabolism: from sand fly gut to human macrophage. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2008;22(2):590–602.
24. Burchmore RJ, Barrett MP, Life in vacuoles—nutrient acquisition by Leishmania amastigotes. International journal for parasitology. 2001;31(12):1311–20. Epub 2001/09/22. 11566299
25. De Rycker M, O'Neill S, Joshi D, Campbell L, Gray DW, Fairlamb AH, A static-cidal assay for Trypanosoma brucei to aid hit prioritisation for progression into drug discovery programmes. PLoS Negl Trop Dis. 2012;6(11):e1932. Epub 2012/12/05. doi: 10.1371/journal.pntd.0001932 23209868
26. Dandapani S, Marcaurelle LA, Grand challenge commentary: Accessing new chemical space for 'undruggable' targets. Nature chemical biology. 2010;6(12):861–3. doi: 10.1038/nchembio.479 21079589
27. Brenk R, Schipani A, James D, Krasowski A, Gilbert IH, Frearson J, et al. Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. ChemMedChem. 2008;3(3):435–44. Epub 2007/12/08. 18064617
28. Lowe JT, Lee MDt, Akella LB, Davoine E, Donckele EJ, Durak L, et al. Synthesis and profiling of a diverse collection of azetidine-based scaffolds for the development of CNS-focused lead-like libraries. The Journal of organic chemistry. 2012;77(17):7187–211. doi: 10.1021/jo300974j 22853001
29. Marcaurelle LA, Comer E, Dandapani S, Duvall JR, Gerard B, Kesavan S, et al. An aldol-based build/couple/pair strategy for the synthesis of medium- and large-sized rings: discovery of macrocyclic histone deacetylase inhibitors. Journal of the American Chemical Society. 2010;132(47):16962–76. doi: 10.1021/ja105119r 21067169
30. Lovering F, Bikker J, Humblet C, Escape from flatland: increasing saturation as an approach to improving clinical success. Journal of medicinal chemistry. 2009;52(21):6752–6. doi: 10.1021/jm901241e 19827778
31. Patterson S, Wyllie S, Stojanovski L, Perry MR, Simeons FR, Norval S, et al. The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral Leishmaniasis. Antimicrob Agents Chemother. 2013;57(10):4699–706. doi: 10.1128/AAC.00722-13 23856774
32. DNDi. DNDi R&D Projects.
33. Duffy KJ, Darcy MG, Delorme E, Dillon SB, Eppley DF, Erickson-Miller C, et al. Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis. Journal of medicinal chemistry. 2001;44(22):3730–45. 11606138
34. Yamamura Y, Ogawa H, Chihara T, Kondo K, Onogawa T, Nakamura S, et al. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science. 1991;252(5005):572–4. 1850553
35. Don R, Ioset JR, Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections. Parasitology. 2014;141(1):140–6. Epub 2013/08/30. doi: 10.1017/S003118201300142X 23985066
36. Siqueira-Neto JL, Moon S, Jang J, Yang G, Lee C, Moon HK, et al. An Image-Based High-Content Screening Assay for Compounds Targeting Intracellular Leishmania donovani Amastigotes in Human Macrophages. Plos Neglect Trop D. 2012;6(6):e1671. Epub 2012/06/22.
37. Aulner N, Danckaert A, Rouault-Hardoin E, Desrivot J, Helynck O, Commere PH, et al. High Content Analysis of Primary Macrophages Hosting Proliferating Leishmania Amastigotes: Application to Anti-leishmanial Drug Discovery. Plos Neglect Trop D. 2013;7(4).
38. Ephros M, Bitnun A, Shaked P, Waldman E, Zilberstein D, Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes. Antimicrob Agents Chemother. 1999;43(2):278–82. 9925518
39. Naisbitt DJ, Ruscoe JE, Williams D, O'Neill PM, Pirmohamed M, Park BK, Disposition of amodiaquine and related antimalarial agents in human neutrophils: implications for drug design. The Journal of pharmacology and experimental therapeutics. 1997;280(2):884–93. 9023303
40. Perez-Victoria FJ, Sanchez-Canete MP, Castanys S, Gamarro F, Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites. The Journal of biological chemistry. 2006;281(33):23766–75. 16785229
41. Perez-Victoria FJ, Gamarro F, Ouellette M, Castanys S, Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. The Journal of biological chemistry. 2003;278(50):49965–71. 14514670
42. Cobby J, Mayersohn M, Selliah S, The rapid reduction of disulfiram in blood and plasma. The Journal of pharmacology and experimental therapeutics. 1977;202(3):724–31. 197231
43. Gupta S, Yardley V, Vishwakarma P, Shivahare R, Sharma B, Launay D, et al. Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis. The Journal of antimicrobial chemotherapy. 2015;70(2):518–27. doi: 10.1093/jac/dku422 25389223
44. Mukkavilli R, Pinjari J, Patel B, Sengottuvelan S, Mondal S, Gadekar A, et al. In vitro metabolism, disposition, preclinical pharmacokinetics and prediction of human pharmacokinetics of DNDI-VL-2098, a potential oral treatment for Visceral Leishmaniasis. Eur J Pharm Sci. 2014;65:147–55. Epub 2014/09/28. doi: 10.1016/j.ejps.2014.09.006 25261338
45. Mulrooney CA, Lahr DL, Quintin MJ, Youngsaye W, Moccia D, Asiedu JK, et al. An informatic pipeline for managing high-throughput screening experiments and analyzing data from stereochemically diverse libraries. Journal of computer-aided molecular design. 2013;27(5):455–68. doi: 10.1007/s10822-013-9641-y 23585218